RSPH vs XLV

Key Takeaways

• RSPH uses an equal-weight methodology, giving every health care name in the S&P 500 roughly the same influence, while XLV is market-capitalization weighted and heavily concentrated in a handful of mega-cap leaders.
• Cost is a decisive structural gap: XLV charges an expense ratio of about 0.08%, versus 0.40% for RSPH.
• RSPH reduces single-stock concentration risk and tilts toward smaller, faster-growing health care names, whereas XLV provides deeper liquidity and broader institutional adoption.
• Both funds offer broad sector exposure, but their performance drivers differ sharply: XLV is powered by mega-cap pharmaceutical and biotech momentum, while RSPH is more sensitive to mid-cap breadth and rotation.
• Tickeron AI Verdict: XLV — the AI currently favors XLV for its lower cost, superior liquidity, and consistent large-cap trend leadership.

Introduction

Investors seeking health care exposure through exchange-traded funds (ETFs) frequently encounter two structurally different products: the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and the Health Care Select Sector SPDR Fund (XLV). Although both draw their holdings from the health care segment of the S&P 500, they represent fundamentally different strategies rather than direct substitutes. This ETF comparison matters because the choice between equal weighting and market-cap weighting has real implications for concentration, volatility, cost, and return patterns. Understanding these structural differences helps investors align their sector exposure and relative positioning with their risk tolerance and long-term objectives.

Invesco S&P 500 Equal Weight Health Care ETF (RSPH) Overview

RSPH is a passively managed fund that tracks the S&P 500 Equal Weight Health Care Index. Unlike a conventional cap-weighted fund, it assigns each constituent an approximately equal weight and rebalances quarterly to restore that balance. The fund holds roughly 61 stocks spanning the health care sector, with a portfolio weighted toward health care equipment and supplies, health care providers and services, and life sciences tools and services, alongside meaningful biotechnology and pharmaceutical allocations.

Because every name carries a similar weight, no single company dominates. Representative top holdings are spread at around 2% each across companies such as MRNA, ISRG, VEEV, and MTD. The fund carries an expense ratio of 0.40% and offers a distinctive, low-concentration route to sector exposure, though it is smaller and less liquid than its cap-weighted peer.

Health Care Select Sector SPDR Fund (XLV) Overview

XLV is a passively managed, market-capitalization-weighted fund that seeks to track the Health Care Select Sector Index, composed of S&P 500 companies classified in the health care sector. The fund holds roughly 63 stocks, but its returns are dominated by the largest names. The top holdings include LLY at roughly 15%, JNJ near 10%, and ABBV above 7%, followed by UNH, MRK, TMO, and AMGN.

With a low expense ratio of about 0.08%, deep trading volume, and multi-decade track record dating to 1998, XLV is among the most established and liquid health care ETFs available. Its cap-weighted design concentrates risk and reward in mega-cap pharmaceutical and biotech leaders.

Industry and Thematic Backdrop

Health care sits at the intersection of several powerful long-term themes: an aging population, rising global demand for medical innovation, and accelerating progress in areas such as weight-loss therapies, oncology, and medical technology. At the same time, the sector faces meaningful headwinds, including drug-pricing policy debates, regulatory scrutiny, and ongoing cost pressures across managed care and health care services.

In recent market cycles, investor attention has rotated toward pharmaceutical innovators with strong earnings momentum and durable pipelines, which has favored larger, cap-weighted positions. Meanwhile, higher interest rates have pressured valuations for growth-oriented and smaller health care companies, a dynamic that affects equal-weight exposure disproportionately. These forces shape how the two funds respond to macro shifts and sector rotation.

Performance and Positioning Comparison

Over recent months and recent market cycles, the two funds have delivered broadly similar directional exposure but with different drivers. XLV has benefited from the strength of its largest holdings, as mega-cap pharmaceutical leaders posted resilient earnings and benefited from innovation-driven momentum. Its cap-weighted structure means relative performance rises and falls with a small group of heavyweights, producing more concentrated risk but also clearer trend consistency.

RSPH, by contrast, is more sensitive to market breadth. When investors rotate into mid-cap and smaller health care names, equal weighting tends to shine; when mega-caps lead, it can lag. Its lower concentration reduces idiosyncratic risk but introduces greater sensitivity to smaller-company earnings cycles and valuation swings. On relative positioning, XLV offers lower cost and higher liquidity, while RSPH offers more balanced diversification.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending names, breakout candidates, and market opportunities far more efficiently than manual screening. Explore the AI Screener to refine your own health care and sector-level searches.

Tickeron AI Verdict

Weighing cost efficiency, liquidity, diversification profile, and trend consistency, Tickeron's AI would currently favor XLV over RSPH. The materially lower expense ratio, deeper trading volume, and established large-cap leadership tilt the probabilistic balance toward the cap-weighted fund in the present environment. While RSPH offers compelling diversification for investors seeking reduced single-stock concentration, XLV currently presents a structurally more efficient and liquid vehicle for capturing broad health care sector exposure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations